Pricing

Vertex Pharmaceuticals, Inc (VRTX)

followers ·
Sector: HEALTH CARE
Industry: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS
CEO: Reshma Kewalramani
Employees: 4,800
Web site: vrtx.com
50 NORTHERN AVENUE, BOSTON, MA, 02210
6173416393
Stock Split History
Date Ratio
2000-08-24 2:1
All 13F Filers Prior Change Hedge Funds 1 Prior Change
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial.
Please log in first to see chart
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% Change in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available